1.Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978–2013. Journal of the National Cancer Institute. 2018;110(4):354–61.
2.Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017;67(1):7–30.
3.Fambrini M, Sorbi F, Sisti G, Cioni R, Turrini I, Taddei G, et al. Endometrial carcinoma in high-risk populations: is it time to consider a screening policy? Cytopathology: official journal of the British Society for Clinical Cytology. 2014;25(2):71–7.
4.Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS, International Collaboration to Harmonise O, et al. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG: an international journal of obstetrics and gynaecology. 2016;123(11):1761–8.
5.Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC cancer. 2015;15:396.
6.Simmons AR, Baggerly K, Bast RC, Jr. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology. 2013;27(6):548–56.
7.Aggarwal P, Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas. 2010;67(1):46–53.
8.Chen Y, Ren YL, Li N, Yi XF, Wang HY. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis. European review for medical and pharmacological sciences. 2016;20(10):1974–85.
9.Bolstad N, Oijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33(1):141–8.
10.Kamei M, Yamashita S, Tokuishi K, Hashioto T, Moroga T, Suehiro S, et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer research. 2010;30(11):4779–83.
11.Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clinical chemistry and laboratory medicine. 2012;50(12):2181–8.
12. Day RS, McDade KK, Chandran UR, Lisovich A, Conrads TP, Hood BL, et al. Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC bioinformatics, 2011; 12: 213.
13.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic acids research. 2015;43(7):e47.
14.Hardcastle TJ. Generalized empirical Bayesian methods for discovery of differential data in high-throughput biology. Bioinformatics. 2016;32(2):195–202.
15.Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009;4(1):44–57.
16.Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic acids research. 2015;43(Database issue):D447–52.
17.Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research. 2003;13(11):2498–504.
18.Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC bioinformatics. 2003;4:2.
19.Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic acids research. 2009;37(Database issue):D105–10.
20.Li JH et al: starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data, Nucleic Acids Res. 2014 Jan;42:D92–7
21.Zhou KR, Liu S, Cai L et al: starBase: decoding the atlas of miRNA-target, RNA-RNA and protein-RNA interactions.
22.Oliveros, J. C. (2007–2015) Venny. An interactive tool for comparing lists with Venn’s diagrams. https://bioinfogp.cnb.csic.es/tools/venny/index.html
23.Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J, Zhao M. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Medical oncology. 2016;33(11):130.
24.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66(1):7–30.
25.Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nature reviews Genetics. 2010;11(9):597–610.
26.Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
27.Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer. 2006;6(11):857–66.
28.Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(21):5972–82.
29.Rao Q, Shen Q, Zhou H, Peng Y, Li J, Lin Z. Aberrant microRNA expression in human cervical carcinomas. Medical oncology. 2012;29(2):1242–8.
30.Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR–200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Annals of surgery. 2014;259(4):735–43.
31.Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR–200b inhibits prostate cancer EMT, growth and metastasis. PloS one. 2013;8(12):e83991.
32.Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, et al. MicroRNA–200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Annals of surgical oncology. 2012;19 Suppl 3:S656–64.
33.Wong CM, Wei L, Au SL, Fan DN, Zhou Y, Tsang FH, et al. MiR–200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget. 2015;6(15):13658–70.
34.Dai Y, Xia W, Song T, Su X, Li J, Li S, et al. MicroRNA–200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC–1A cells. Nucleic acid therapeutics. 2013;23(1):29–34.
35.Antolin S, Calvo L, Blanco-Calvo M, Santiago MP, Lorenzo-Patino MJ, Haz-Conde M, et al. Circulating miR–200c and miR–141 and outcomes in patients with breast cancer. BMC cancer. 2015;15:297.
36.Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye F, et al. miR–200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 2015;6(33):34968–78.
37.Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British journal of cancer. 2014;110(10):2462–71.
38.Gao YC, Wu J. MicroRNA–200c and microRNA–141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36(6):4843–50.
39.Karaayvaz M, Zhang C, Liang S, Shroyer KR, Ju J. Prognostic significance of miR–205 in endometrial cancer. PloS one. 2012;7(4):e35158.
40.Snowdon J, Zhang X, Childs T, Tron VA, Feilotter H. The microRNA–200 family is upregulated in endometrial carcinoma. PloS one. 2011;6(8):e22828.
41.Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PloS one. 2011;6(3):e18286.
42.Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008;14(9):2690–5.
43.Uhlmann S, Zhang JD, Schwager A, Mannsperger H, Riazalhosseini Y, Burmester S, et al. miR–200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR–200a/141 in breast cancer. Oncogene. 2010;29(30):4297–306.
44.Sun T, Wang C, Xing J, Wu D. miR–429 modulates the expression of c-myc in human gastric carcinoma cells. European journal of cancer. 2011;47(17):2552–9.
45.Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. microRNA expression profile in stage III colorectal cancer: circulating miR–18a and miR–29a as promising biomarkers. Oncology reports. 2013;30(1):320–6.
46.Lu YB, Hu JJ, Sun WJ, Duan XH, Chen X. Prognostic value of miR–141 downregulation in gastric cancer. Genetics and molecular research: GMR. 2015;14(4):17305–11.
47.Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urologic oncology. 2011;29(6):794–801 e1.
48.Wu CT, Lin WY, Chang YH, Lin PY, Chen WC, Chen MF. DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer. Oncotarget. 2015;6(27):24119–31.
49.Zhou Y, An Q, Guo RX, Qiao YH, Li LX, Zhang XY, et al. miR424–5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway. Life sciences. 2017;171:9–15.
50.Li Q, Qiu XM, Li QH, Wang XY, Li L, Xu M, et al. MicroRNA–424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7. Oncology reports. 2015;33(5):2354–60.
51.Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, et al. miR–195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015;21(21):4922–34.
52.Tsukamoto O, Miura K, Mishima H, Abe S, Kaneuchi M, Higashijima A, et al. Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecologic oncology. 2014;132(3):715–21.
53.Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, et al. MicroRNA–195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 2013;58(2):642–53.
54.Sauer K, Lehner CF. The role of cyclin E in the regulation of entry into S phase. Progress in cell cycle research. 1995;1:125–39.
55.Han Z, Zhang Y, Yang Q, Liu B, Wu J, Zhang Y, et al. miR–497 and miR–34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget. 2015;6(15):13149–63.
56.Liang Y, Gao H, Lin SY, Goss JA, Brunicardi FC, Li K. siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model. PloS one. 2010;5(9):e12860.
57.Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, et al. Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene. 2012;31(33):3785–95.
58.Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer. 2010;116(11):2621–34.
59.Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Seminars in cancer biology. 2005;15(4):319–26.
60.Lopez-Beltran A, MacLennan GT, Montironi R. Cyclin E as molecular marker in the management of breast cancer: a review. Analytical and quantitative cytology and histology. 2006;28(2):111–4.
61.Zhang X, Hu S, Zhang X, Wang L, Zhang X, Yan B, et al. MicroRNA–7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochemical and biophysical research communications. 2014;443(3):1078–84.
62.Wang J, Xu G, Shen F, Kang Y. miR–132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(5):4859–65.
63.Zubillaga-Guerrero MI, Alarcon-Romero Ldel C, Illades-Aguiar B, Flores-Alfaro E, Bermudez-Morales VH, Deas J, et al. MicroRNA miR–16–1 regulates CCNE1 (cyclin E1) gene expression in human cervical cancer cells. International journal of clinical and experimental medicine. 2015;8(9):15999–6006.
64.Matsushita R, Seki N, Chiyomaru T, Inoguchi S, Ishihara T, Goto Y, et al. Tumour-suppressive microRNA–144–5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer. British journal of cancer. 2015;113(2):282–9.